Identification and characterization of IS1 transposition in plasmid amplification mutants of E. coli clones producing DNA vaccines

Applied Microbiology and Biotechnology

Volumn 73, Issue 4, 2006, Pages 815-826

  Prather, Kristala L Jones ^a,b   Edmonds, M Celina ^a   Herod, Jerrell W ^c  

^a MERCK RESEARCH LABORATORIES   (United States)

^b USA   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

DNA vaccine; IS1 transposition; Q PCR; RFLP

Indexed keywords

DNA VACCINE; IS1 TRANSPOSITION; Q-PCR;

CELLS; CLONING; DNA; ESCHERICHIA COLI; VACCINES;

BIOTECHNOLOGY;

DNA VACCINE; PLASMID DNA;

AMPLIFICATION; BACTERIUM; CLONE; DNA; EXPERIMENTAL STUDY; FERMENTATION; HUMAN IMMUNODEFICIENCY VIRUS; MUTATION; PLASMID; POLYMERASE CHAIN REACTION; POLYMORPHISM; VACCINE;

ARTICLE; BACTERIAL GENOME; CLONE; CONTROLLED STUDY; CULTURE MEDIUM; ESCHERICHIA COLI; FED BATCH FERMENTATION; GENE; GENE AMPLIFICATION; GENE INSERTION; GENE MUTATION; GENE PROBE; GENE REPLICATION; GENE SEQUENCE; GROWTH CURVE; MUTANT; NEOMYCIN RESISTANCE GENE; NONHUMAN; NUCLEOTIDE SEQUENCE; PLASMID; POLYMERASE CHAIN REACTION; QUANTITATIVE ANALYSIS; RESTRICTION FRAGMENT LENGTH POLYMORPHISM;

DNA FINGERPRINTING; DNA TRANSPOSABLE ELEMENTS; DNA, BACTERIAL; DRUG RESISTANCE, BACTERIAL; ELECTROPHORESIS, AGAR GEL; ESCHERICHIA COLI; GENETIC VECTORS; HIV; PLASMIDS; POLYMERASE CHAIN REACTION; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; RECOMBINATION, GENETIC; VACCINES, DNA;

ESCHERICHIA COLI;

EID: 33751510492     PISSN: 01757598     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00253-006-0532-1     Document Type: Article

References (51)

1. Barouch DH, Santra S, Schmitz JE, Kuroda MJ, Fu TM, Wagner W, Bilska M, Craiu A, Zheng XX, Krivulka GR, Beaudry K, Lifton MA, Nickerson CE, Trigona WL, Punt K, Freed DC, Guan L, Dubey S, Casimiro D, Simon A, Davies ME, Chastain M, Strom TB, Gelman RS, Montefiori DC, Lewis MG, Emini EA, Shiver JW, Letvin NL (2000) Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination. Science 290:486-492
2. Boyd AC, Popp F, Michaelis U, Davidson H, Davidson-Smith H, Doherty A, McLachlan G, Porteous DJ, Seeber S (1999) Insertion of natural intron 6a-6b into a human cDNA-derived gene therapy vector for cystic fibrosis improves plasmid stability and permits facile RNA/DNA discrimination. J Gene Med 1:312-321
3. Carnes AE (2005) Fermentation design for the manufacture of therapeutic plasmid DNA. BioProcess Int 3:36-44
4. Casimiro DR, Tang A, Perry HC, Long RS, Chen M, Heidecker GJ, Davies M-E, Freed DC, Persaud NV, Dubey S, Smith JG, Havlir D, Richman D, Chastain MA, Simon AJ, Fu T-M, Emini EA, Shiver JW (2002) Vaccine-induced immune responses in rodents and nonhuman primates by use of a humanized Human Immunodeficiency Virus Type 1 pol gene. J Virol 76:185-194
5. Caulfield MJ, Wang S, Smith JG, Tobery TW, LIu X, Davies M-E, Casimiro DR, Fu T-M, Simon A, Evans RK, Emini EA, Shiver JW (2002) Sustained peptide-specific gamma interferon T-cell response in Rhesus macaques immunized with human immunodeficiency virus gag DNA vaccines. J Virol 76:10038-10043
6. Chartrain M, Bentley LK, Krulewicz BA, Listner KM, Sun W-J, Lee CB (2005) Process for large scale production of plasmid DNA by E. coli fermentation. WO 2005/078115. Merck, USA
7. Chen W (1999) Automated high-yield fermentation of plasmid DNA in Escherichia coli. US Patent 5,995,323 (American Home Products)
8. Chen J-H, Yeh H-T (1997) The seventh copy of IS1 in Escherichia coli W3110 belongs to the IS1A(IS1E) type which is the only IS1 type that transposes from chromosome to plasmids. Proc Natl Sci Counc Repub China B 21:100-105
9. Chew LCK, Tacon WCA, Cole JA (1986) Increased stability of maintenance of pAT153 in Escherichia coli HB101 due to transposition of IS1 from the chromosome into the tetracycline resistance region of pAT153. FEMS Microbiol Lett 36:275-280
10. Deonier RC (1987) Locations of native insertion sequence elements. In: Neidhardt F (ed) Escherichia coli and Salmonella typhimurium: cellular and molecular biology. American Society for Microbiology, Washington, DC, pp 982-989
11. Donnelly J, Berry K, Ulmer JB (2003) Technical and regulatory hurdles for DNA vaccines. Int J Parasitol 33:457-467
12. Dower WJ, Miller JF, Ragsdale CW (1988) High efficiency transformation of E. coli by high voltage electroporation. Nucleic Acids Res 16:6127-6145
13. Dunham SP (2002) The application of nucleic acid vaccines in veterinary medicine. Res Vet Sci 73:9-16
14. Galas D, Calos MP, Miller JH (1980) Sequence analysis of Tn9 insertions in the lacZ gene. J Mol Biol 144:19-41
15. Gurunathan S, Klinman DM, Seder RA (2000) DNA vaccines: immunology, application, and optimization. Annu Rev Immunol 18:927-974
16. Hall BG (1998) Activation of the bgl operon by adaptive mutation. Mol Biol Evol 15:1-5
17. Hensley S (2005) Vaccines that keep salmon safe to eat may help humans. In: Wall St. Journal (Eastern edition). New York, p B.1
18. Itoh M, Suzuki T, Kimata Y, Kawai K, Horitsu H, Takamizawa K (1994) Cadmium resistance acquirement by IS1 transposition into Escherichia coli C600. J Ferment Bioeng 78:466-468
19. Kitamura K, Torii Y-i, Matsuoka C, Yamamoto K (1995) DNA sequence changes in mutations in the tonB gene on the chromosome of Escherichia coli K12: insertion elements dominate the spontaneous spectra. Jpn J Genet 70:35-46
20. Klotsky R-A, Schwartz I (1987) Measurement of cat expression from growth-rate-regulated promoters employing b-lactamase activity as an indicator of plasmid copy number. Gene 55: 141-146
21. Kobayashi K, Tsukagoshi N, Aono R (2001) Suppression of hypersensitivity of Escherichia coli acrB mutant to organic solvents by integrational activation of the acrEF operon with the IS1 or IS2 element. J Bacteriol 183:2646-2653
22. Leitner WW, Thalhamer J (2003) DNA vaccines for non-infectious diseases: new treatments for tumour and allergy. Expert Opin Biol Ther 3:627-638
23. Lekutis C, Shiver JW, Liu MA, Letvin NL (1997) HIV-1 env DNA vaccine administered to Rhesus monkeys elicits MHC Class IIrestricted CD4+ T helper cells that secrete IFN-g and TNF-a. J Immunol 158:4471-4477
24. Liang X, Fu T-M, Xie H, Emini EA, Shiver JW (2002) Development of HIV-1 Nef vaccine components: immunogenicity study of Nef mutants lacking myristoylation and dileucine motif in mice. Vaccine 20:3413-3421
25. Lin-Chao S, Bremer H (1986) Effect of the bacterial growth rate on replication control of plasmid pBR322 in Escherichia coli. Mol Gen Genet 203:143-149
26. -ΔΔC method. Methods 25:402-408
27. Lowrie DB (1999) DNA vaccines against tuberculosis. Curr Opin Mol Ther 1:30-33
28. Montgomery DL, Shiver JW, Leander KR, Perry HC, Friedman A, Martinez D, Ulmer JB, Donnelly JJ, Liu MA (1993) Heterologous and homologous protection against Influenza A by DNA vaccination: optimization of DNA vectors. DNA Cell Biol 12:777-783
29. Mwau M, McMichael AJ (2003) A review of vaccines for HIV prevention. J Gene Med 5:3-10
30. Naas T, Blot M, Fitch WM, Arber W (1994) Insertion sequence-related genetic variation in resting Escherichia coli K-12. Genetics 136:721-730
31. Naas T, Blot M, Fitch WM, Arber W (1995) Dynamics of IS-related genetic rearrangements in resting Escherichia coli K-12. Mol Biol Evol 12:198-207
32. Nakahama K, Itoh Y, Fujisawa Y, Kikuchi M (1986) Increased expression of hepatitis B virus surface antigen gene in Escherichia coli by IS1 insertion. Appl Microbiol Biotechnol 25:262-266
33. Nakamura K, Inouye M (1981) Inactivation of the Serratia marcescens gene for the lipoprotein in Escherichia coli by insertion sequences, IS1 and IS5; sequence analysis of junction points. Mol Gen Genet 183:107-114
34. Namdev PK, Irwin N, Thompson BG, Gray MR (1993) Effect of oxygen fluctuations on recombinant Escherichia coli fermentation. Biotechnol Bioeng 41:666-670
35. Ohtsubo E, Sekine Y (1996) Bacterial insertion sequences. In: Saedler H, Gierl A (eds) Transposable elements. Springer, Berlin Heidelberg New York, pp 1-26
36. Okonkowski J, Kizer-Bentley L, Listner K, Robinson D, Chartrain M (2005) Development of a robust, versatile, and scalable inoculum train for the production of a DNA vaccine. Biotechnol Prog 21:1038-1047
37. Powell K (2004) DNA vaccines - back in the saddle again? Nat Biotechnol 22:799-801
38. Prather KJ, Sagar S, Murphy J, Chartrain M (2003) Industrial scale production of plasmid DNA for vaccine and gene therapy: plasmid design, production, and purification. Enzyme Microb Technol 33:865-883
39. Reinikainen P, Korpela K, Nissinen V, Olkku J, Soderlund H, Markkanen P (1989) Escherichia coli plasmid production in fermenter. Biotechnol Bioeng 33:386-393
40. Reinikainen P, Virkajärvi I (1989) Escherichia coli growth and plasmid copy numbers in continuous cultivations. Biotechnol Lett 11:222-230
41. Rodriguez H (1992) An Escherichia coli plasmid-based, mutational system in which supF mutants are selectable: insertion elements dominate the spontaneous spectra. Mutat Res 270:219-231
42. Schirrmacher V (2005) T cell-mediated immunotherapy of metastases: state of the art in 2005. Expert Opin Biol Ther 5:1051-1068
43. Schmidt T, Friehs K, Flaschel E, Schleef M (2003) Method for the isolation of ccc plasmid DNA. US Patent 6,664,078. Qiagen GmbH
44. Seo J-H, Bailey JE (1985) Effects of recombinant plasmid content on growth properties and cloned gene product formation in Escherichia coli. Biotechnol Bioeng 27:1668-1674
45. Seo J-H, Bailey JE (1986) Continuous cultivation of recombinant Escherichia coli - existence of an optimum dilution rate for maximum plasmid and gene-product concentration. Biotechnol Bioeng 28:1590-1594
46. S-enforcement cloning vectors with a synthetic rpsL gene. Gene 121:25-33
47. Tuteja R (2002) DNA vaccine against malaria: a long way to go. Crit Rev Biochem Mol Biol 37:29-54
48. Ulmer JB (2002) Influenza DNA vaccines. Vaccine 20:S74-S76
49. Vilalta A, Whitlow V, Martin T (2002) Real-time PCR determination of Escherichia coli genomic DNA contamination in plasmid preparations. Anal Biochem 301:151-153
50. Zerbib D, Gamas P, Chandler M, Prentki P, Bass S, Galas D (1985) Specificity of insertion of IS1. J Mol Biol 185:517-524
51. Zhang J, Greasham R (1999) Chemically defined media for commercial fermentations. Appl Microbiol Biotechnol 51:407-421